A new study from Northwestern University has found that two widely prescribed type 2 diabetes medications—sulfonylureas and ...

Generic versions of diabetes drug Empagliflozin launched in India, crashing prices by 80-90% on day one post-patent expiry.

Glenmark Pharmaceuticals on Wednesday said it has launched a medication for glycemic control and weight-loss for diabetes ...

Alkem Laboratories has launched a generic medication for type-2 diabetes, chronic kidney disease and heart failure in India ...

Research shows that a common type of diabetes medication could help cancer patients make a better long-term recovery. Many cancer patients go on to develop heart failure -- because of the cancer ...

A widely used diabetes medication, SGLT2 inhibitors, has shown a surprising benefit for cancer patients—protecting their ...

SGLT2 inhibitors, a diabetes medication, may protect the heart and reduce hospitalizations for cancer patients, particularly ...

Dr. Akshay Jain MD, FRCPC, FACE, CCD, ECNU, DABIM, DABOM, Clinical and Research Endocrinologist, talks about novel ...

According to the company's statement, these medications are designed to improve glycemic control in adults with Type 2 Diabetes while also reducing cardiovascular outcomes in the patients.

India’s drug price regulator has capped retail prices for 53 drug formulations used in treating various diseases and ...

Glenmark Pharmaceuticals launches Empagliflozin, an SGLT2 inhibitor, in India under the brand name Glempa for glycemic ...

Empagliflozin is an SGLT-2 (Sodium-Glucose Co-Transporter-2) inhibitor indicted for use in the treatment of type-2 diabetes mellitus.